Racial and Socioeconomic Disparities Exist in Peanut OIT Populations
Oral immunotherapy (OIT) is a time and resource intensive treatment for food allergy that requires frequent clinic visits. We hypothesized that disparities may exist between the peanut OIT population and the general peanut allergic population in that higher socioeconomic status groups access OIT at higher rates. (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - February 1, 2024 Category: Allergy & Immunology Authors: Lindsay Gallagher, Charles Schuler, Jonathan Troost, Ian Slack, Georgiana Sanders, James Baker, Jennifer Smith, Kelly O'Shea Source Type: research
Modified Toddler Peanut Desensitization Protocol in Real-World Clinical Practice
We aimed to evaluate the effectiveness and safety of real-life Oral Immune Therapy using crushed peanuts versus peanut puffs. (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - February 1, 2024 Category: Allergy & Immunology Authors: Adnan Al Ali, Karen Sigman, Christine McCusker, Mohammed Kaouache, Moshe Ben-shoshan, Sarife Saker, Greg Shand Source Type: research
Safety and Tolerability of Single-Dose Initial Day Dosing in a Preschool Clinical Peanut OIT Program
Based on our previous experience with oral immunotherapy (OIT) and following the IMPACT trial demonstrating the potential for remission in preschool children, we launched an early peanut OIT (e-POIT) clinical program for preschoolers 6 months to 4 years of age. No products are yet approved in this age group, and delivering low initial doses reliably is technically challenging. (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - February 1, 2024 Category: Allergy & Immunology Authors: Codi Horton, Chelsea Leef, Idil Ezhuthachan, Tricia Lee, Gerald Lee, Melinda Rathkopf, Brian Vickery Source Type: research
Safety of Peanut Oral Immunotherapy in Preschoolers at a Pediatric Academic Food Allergy Center
Following publication of the IMPACT study, we launched an early peanut oral immunotherapy (e-POIT) program for peanut-allergic children 6 months to 4 years of age. We aimed to capture adverse events (AEs) related to dosing for all e-POIT patients. (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - February 1, 2024 Category: Allergy & Immunology Authors: Brian Vickery, Codi Horton, Chelsea Leef, Shasha Bai, Idil Ezhuthachan, Tricia Lee, Gerald Lee, Melinda Rathkopf Source Type: research
Peanut Oral Food Challenges are Frequently Passed in Low-Risk Populations Referred for Oral Immunotherapy
Patients (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - February 1, 2024 Category: Allergy & Immunology Authors: Candice Gard, Georgiana Sanders, Kelly O'Shea Source Type: research
Transitioning from Peanut Allergen Powder-dnfp to Peanuts
Peanut Allergen Powder-dnfp (PAP) is an oral desensitization product approved by the FDA for peanut allergy. After an initial dose escalation phase, continuous exposure to peanut protein maintains desensitization and continued immunomodulation. We hypothesize that transitioning to food products to maintain desensitization after dose escalation is a safe alternative to continuation of PAP. (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - February 1, 2024 Category: Allergy & Immunology Authors: Saad Anjum, Christina Ciaccio Source Type: research
Patient and Caregiver Satisfaction and Quality of Life during Peanut Oral Immunotherapy at a Pediatric Academic Food Allergy Center
Although peanut and other forms of oral immunotherapy (OIT) have emerged as an increasingly accepted treatment option, gaps remain in the understanding of patient- and caregiver-reported outcomes. (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - February 1, 2024 Category: Allergy & Immunology Authors: Chelsea Leef, Codi Horton, Heather Porter, Idil Ezhuthachan, Tricia Lee, Gerald Lee, Melinda Rathkopf, Brian Vickery Source Type: research
Long-Term Maintenance of Peanut Oral Immunotherapy in Patients Ages 4 and Older
Peanut oral immunotherapy (OIT) in patients ≥4 years old is generally considered long-term treatment that requires prolonged, daily ingestion to maintain the desensitized state. Due to the risks, requirements, and constraints associated with daily dosing, we sought to determine the number of patients ≥4 years old who were continuing treat ment at least one year after reaching maintenance. (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - February 1, 2024 Category: Allergy & Immunology Authors: Sarah Paik Source Type: research
Long-term effectiveness of peanut oral immunotherapy: beyond bite protection
We examined long-term outcomes in a pediatric cohort undergoing peanut OIT. (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - February 1, 2024 Category: Allergy & Immunology Authors: Taha Akhtar, Chen Rosenberg Source Type: research
Efficacy of peanut oral immunotherapy is not impacted by the development of persistent gastrointestinal symptoms
Despite its efficacy, oral immunotherapy (OIT) can be complicated by adverse events, such as persistent gastrointestinal symptoms (PGIS). Whether these symptoms impact OIT outcomes is not fully understood. (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - February 1, 2024 Category: Allergy & Immunology Authors: Sayantani Sindher, Julie Thompson, Shu Cao, Scott Boyd, Stephen Galli, Kari Nadeau, R. Sharon Chinthrajah Source Type: research
Markers associated with adverse reactions during peanut oral food challenge after peanut oral immunotherapy
FDA-approved peanut oral immunotherapy (pOIT) is a novel peanut allergy therapy to achieve higher allergen reaction threshold. However, pOIT also increases the risk of allergic reactions during therapy. Peanut allergen powder includes peanut subtypes Ara h1, Ara h2, and Ara h6. We hypothesized that patients who failed plain peanut oral food challenge (pOFC) after pOIT may have higher IgE levels of certain peanut allergen subtypes. (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - February 1, 2024 Category: Allergy & Immunology Authors: Erin Kim, Bryce Binstadt, Nancy Ott Source Type: research
Peanut vs Other Food Oral Immunotherapy: Trends from an Outpatient Allergy Clinic in Boise, ID
Food allergy (FA) is a burdensome and increasing problem, affecting one ’s psychological development and quality of life. Management of food allergy relies primarily on avoidance of exposure to suspected or proven foods, however, is often inadequate. Oral immunotherapy (OIT) for FA has been studied. We compared peanut vs other foods OIT to find clinically significant trends in OIT treatments in an outpatient allergy clinic in Boise, ID. (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - February 1, 2024 Category: Allergy & Immunology Authors: Kahlil Monje, Mojtaba Sadegh, Neetu Talreja Source Type: research
Long-term Safety Results of Epicutaneous Immunotherapy (EPIT) with Viaskin Peanut in Peanut-Allergic Children Aged 4-11 Years in the Phase 3 PEOPLE Study
Previously reported interim results from PEOPLE (PEPITES Open-Label Extension) demonstrated Viaskin Peanut 250 μg (VP250) led to continued treatment response and was well-tolerated out to 3 years. Here we report PEOPLE end-of-study safety results. (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - February 1, 2024 Category: Allergy & Immunology Authors: David Fleischer, Lara Ford, Gordon Sussman, William Yang, Peter Smith, Jacqueline Pongracic, Roxanne Oriel, Hugh Sampson Source Type: research
Effect of Pre-existing Atopic Disease on Pediatric Peanut Sublingual Immunotherapy (SLIT) Outcomes
Peanut SLIT has been shown to produce clinically significant desensitization and remission in peanut-allergic children. These patients have high prevalence of atopic comorbidities, however, there is limited data evaluating the impact of pre-existing atopic disease on SLIT outcomes. (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - February 1, 2024 Category: Allergy & Immunology Authors: Mayuran Ravindran, J. Andrew Bird, Corinne Keet, Yamini Virkud, Lauren Herlihy, Michael Kulis, A. Wesley Burks, Edwin Kim Source Type: research
IGNX001 Abrogates Peanut-mediated Mast Cell Degranulation and Murine Anaphylaxis
New treatment paradigms are urgently needed in peanut allergy where the standard of care is allergen avoidance and rescue epinephrine. While promising in some patient subsets, desensitization through chronic allergen exposure is challenged by compliance, adverse events, and long timelines for achieving desired outcomes. Peanut allergic individuals would greatly benefit from a therapeutic that avoids these challenges. (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - February 1, 2024 Category: Allergy & Immunology Authors: Derek Croote, Joyce Wong, Paige Creeks, Venu Aruva, Jessica Grossman, Roger Ferrini, Henry Lowman, Jeffrey Landers, Jessica O'Konek, Roger Thomas Source Type: research
